Recent News

• 06.04.2025 - U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
• 05.21.2025 - Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
• 05.16.2025 - Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
• 05.16.2025 - Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
• 05.14.2025 - 5/14/2511:40 AM EDT : BofA Securities 2025 Healthcare Conference
• 05.13.2025 - Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
• 05.13.2025 - 5/13/25 - 5/17/25 : 2025 ASGCT Annual Meeting
• 05.08.2025 - Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
• 05.06.2025 - 5/6/254:30 PM EDT : Sarepta Therapeutics First Quarter 2025 Earnings Call
• 05.06.2025 - Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

Recent Filings

• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.24.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.24.2025 - ARS Annual Report to Security Holders
• 04.24.2025 - DEF 14A Other definitive proxy statements